SEC Form EFFECT filed by Klotho Neurosciences Inc.
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 12, 2025 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 12, 2025 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
DEFR14A - Klotho Neurosciences, Inc. (0001907223) (Filer)
DEF 14A - Klotho Neurosciences, Inc. (0001907223) (Filer)
PRE 14A - Klotho Neurosciences, Inc. (0001907223) (Filer)
4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO, ", Klotho", , or ", the Company", )), a U.S.-based biogenetics company, announces that CEO Dr. Joseph Sinkule will be presenting at the 2026 Biotech Showcase in San Francisco on January 13, 2026 at 11:30AM PT. The Biotech Showcase is to be held January 12-14, 2026 at the Hilton San Francisco Union Square. At the event, the Company will be available for one-on-one meetings with investors and potential partners. To request a meeting, please contact [email protected]. About Klotho Neuroscien
NEW YORK, Nov. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) (the "Company" or "Klotho"), a U.S.-based biogenetics company, announces it has been selected as winner of the Fifth Annual BioTech Breakthrough Award in the "Cell Therapy Innovation of the Year" category. Klotho Neurosciences earned this recognition for its pioneering work developing transformative gene and cell therapies using a patented, secreted form of the human Klotho gene (s-KL) to address devastating neurodegenerative and age-related diseases, including ALS, Alzheimer's disease, and Parkins
NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO, ", Klotho", , or ", the Company", )) a U.S.-based biogenetics company, announces that members of its leadership team will attend Longevity Biotech 2025 in Boston, Massachusetts, on October 22–23, 2025. The conference convenes leaders across biotech, pharma, academia, and venture to advance the development of longevity therapeutics and will be hosted at Wightman Mansion (43 Hawes Street, Brookline/Fenway campus). At the event, the Company will be available for one-on-one meetings with investors and
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB). Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of thera
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer's, and Parkinson's, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he ser
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene." While conducting groundbreaking research at the National Institute of Neuroscience in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while studying mice engineered to overexpress a gene linked to premature aging. Th